Salidroside Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease via AMPK-Dependent TXNIP/NLRP3 Pathway. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.